Compare KZIA & CGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KZIA | CGO |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.8M | 112.3M |
| IPO Year | 2002 | N/A |
| Metric | KZIA | CGO |
|---|---|---|
| Price | $13.59 | $12.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.50 | N/A |
| AVG Volume (30 Days) | ★ 272.9K | 26.4K |
| Earning Date | 06-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.25% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.05 | $10.57 |
| 52 Week High | $17.40 | $13.05 |
| Indicator | KZIA | CGO |
|---|---|---|
| Relative Strength Index (RSI) | 74.57 | 66.02 |
| Support Level | $5.85 | $11.36 |
| Resistance Level | $14.42 | N/A |
| Average True Range (ATR) | 1.32 | 0.21 |
| MACD | 0.23 | 0.02 |
| Stochastic Oscillator | 84.64 | 76.22 |
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.